Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 14;60(3):477.
doi: 10.3390/medicina60030477.

The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis

Lora Stanka Kirigin Biloš  1 , Velimir Altabas  1   2 , Andrea Vukić Dugac  2   3   4 , Maja Baretić  3   5
Affiliations
Review

The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis

Lora Stanka Kirigin Biloš et al. Medicina (Kaunas). .

Abstract

Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in patients with cystic fibrosis (CF). CFRD has been correlated with important clinical outcomes, including poor nutrition, reduced pulmonary function, and earlier mortality. However, clinical decline due to abnormalities of blood glucose (dysglycemia) begins early in CF, before the diagnosis of CFRD by the gold-standard oral glucose tolerance test (OGTT). Continuous glucose monitoring (CGM) has been validated in patients with CF and has been recognized as a valuable tool in detecting early glucose abnormalities in patients with CF. Several CGM parameters have been used to predict CFRD in some but not all studies, and there is no consensus regarding CGM use for diagnostic purposes. Thus, it remains a complementary test to OGTT in CFRD diagnosis. The aim of this review is to provide an update on the pathophysiological mechanisms of CFRD, recent advances in the use of CGM for CFRD screening, and the association between CGM measures and CF-related clinical outcomes.

Keywords: clinical outcomes; continuous glucose monitoring; cystic fibrosis-related diabetes; screening.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Algorithm of pathophysiological mechanisms leading to dysglycemia, abnormal glucose tolerance, and cystic fibrosis-related diabetes in patients with cystic fibrosis.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. O’Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet. 2009;373:1891–1904. doi: 10.1016/S0140-6736(09)60327-5. - DOI - PubMed
    1. De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020;109:893–899. doi: 10.1111/apa.15155. - DOI - PubMed
    1. Norris A.W., Ode K.L., Merjaneh L., Sanda S., Yi Y., Sun X., Engelhardt J.F., Hull R.L. Survival in a bad neighborhood: Pancreatic islets in cystic fibrosis. J. Endocrinol. 2019;241:R35–R50. doi: 10.1530/JOE-18-0468. - DOI - PMC - PubMed
    1. Putman M.S., Norris A.W., Hull R.L., Rickels M.R., Sussel L., Blackman S.M., Chan C.L., Ode K.L., Daley T., Stecenko A.A., et al. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes. Diabetes. 2023;72:677–689. doi: 10.2337/db22-0949. - DOI - PMC - PubMed
    1. Moran A., Becker D., Casella S.J., Gottlieb P.A., Kirkman M.S., Marshall B.C., Slovis B., CFRD Consensus Conference Committee Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: A technical review. Diabetes Care. 2010;33:2677–2683. doi: 10.2337/dc10-1279. - DOI - PMC - PubMed